Literature DB >> 7704502

Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report.

M R Green, J D Cox, A Ardizzoni, R Arriagada, G Bureau, S Darwish, G Deneffe, M Fukuoka, D Joseph, R Komaki.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7704502     DOI： 10.1016/0169-5002(94)91859-7

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  2 in total

1.  Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial.

Authors:  W Eberhardt; G Stamatis; M Stuschke; H Wilke; M R Müller; S Kolks; M Flasshove; J Schütte; M Stahl; L Schlenger; V Budach; D Greschuchna; G Stüben; H Teschler; H Sack; S Seeber
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

2.  Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer.

Authors:  K Haslett; P Koh; A Hudson; W D Ryder; S Falk; D Mullan; B Taylor; R Califano; F Blackhall; C Faivre-Finn
Journal:  Clin Transl Radiat Oncol       Date:  2021-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.